Can tenofovir alafenamide fumarate tablets (Vemlidy) not be stopped once taken?

Tenofovir alafenamide fumarate tablets (Vemlidy/Vemlidy) is regarded as an important choice for long-term antiviral treatment in the management of chronic hepatitis B, and its discontinuation is often a focus of concern for patients. Unlike some short-term antiviral drugs, Vemlidy mainly controls viral replication by inhibiting HBV reverse transcriptase activity, so its efficacy depends on continuous use to maintain stable blood concentration and viral suppression effect.

In clinical practice, whether to discontinue medication needs to be comprehensively evaluated based on the patient's virological indicators, liver function status and immunological response . Abrupt discontinuation may lead to HBV rebound, increased viral load and abnormal liver function, especially in patients who have not yet achieved long-term viral suppression or whose liver recovery is unstable. Therefore, most doctors recommend long-term regular use and regular follow-up to evaluate whether conditions exist for safe discontinuation.

For some patients with specific immunological characteristics or who have completed long-term stable suppression, clinically, gradual discontinuation of the drug may be considered under strict monitoring, but the entire process must be conducted under the guidance of a professional physician and in conjunction with regular liver function and viral load tests to prevent the risk of recurrence. Overseas guidelines also emphasize that the decision to discontinue medication must be made with caution, and one cannot interrupt or adjust the dose at will.

In general, discontinuation of tenofovir alafenamide fumarate tablets is not absolutely prohibited, but requires individualized assessment, strict monitoring and gradual progress. Patients should make adjustments under the guidance of a professional physician. Long-term regular medication is currently the key measure to maintain antiviral efficacy and prevent liver damage. Through scientific management, patients can reduce potential risks while ensuring the efficacy, making the use of tenofovir alafenamide fumarate tablets safer and more controllable.

Reference materials:https://www.vemlidyhcp.com/